How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Organelles are entities within a eukaryotic cell that have a specialised function. Examples of organelles include the nucleus, the endoplasmic reticulum, the Golgi, mitochondria, vacuoles or lysosomes ...

Dara-Abasi Ita writes about trading and investing for Investopedia and Investing.com, and he is an editor at Lawverse magazine. He has written about financial topics, including private equity, asset ...

Dr. JeFreda R. Brown is a financial consultant, Certified Financial Education Instructor, and researcher who has assisted thousands of clients over a more than two-decade career. She is the CEO of ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals insiders reported 6 transactions totaling $589,430.56. Activity included 2 tax payments, 2 sales, and 2 stock awards between July and August 2026. View more Major Holders ...